Table 1.
Approaches inhibiting TGF-b.
| Agent | Target | Phase |
|---|---|---|
| Antisense | ||
| AP12009 | TGF-β1 mRNA | Pre-clinical |
| AP1104/AP15012 | TGF-β2 mRNA | Phase I/II |
| Combined Vaccine/Antisense | ||
| Belagenpumatucel-L (LucanixTM) | TGF-β2 | Phase I/II/III |
| Antibody | ||
| 2G7 | TGF-β1, β2, β3 TGF-β1, β2, β3 | Pre-clinical |
| 1D11 | TGF-β1, β2, β3 | Pre-clinical |
| GC1008 | Phase I/II | |
| Soluble TGF-β receptors | ||
| Soluble TGFβRII:Fc | TGF-β | Pre-clinical |
| Soluble TGFβRIII (βglycan) | TGF-β | Pre-clinical |
| Receptor kinase inhibitors | ||
| SB431542 | TβRI | Pre-clinical |
| Ki 26894 | TβRI | Pre-clinical |
| SD208 | TβRI | Pre-clinical |
| LY2109761 | TβRI/II | Pre-clinical |
| IN-1130 | TβRI ALK-4/7 | Pre-clinical |
| LY2157299 | TβRI | Phase I/II |
| Peptide aptamers | ||
| Trx-xFoxH1b | Smad2–4 | Pre-Clinical |
| Trx-SARA | Smad3–4 | Pre-Clinical |
| PD-L1 Inhibitors and TGF-B Inhibitors | ||
| M7824 | PD-L1 and TGF-β trap | Phase 1 |